Probatebeta
Target

FGFR2

Fibroblast growth factor receptor 2

As of the edition of 20 October 2026, FGFR2 (fibroblast growth factor receptor 2, UniProt P21802) has 29 drugs tested at it and 31 companies on the list, 12 on route A and 8 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P21802
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
In more than one place
Solved structures
65
Disease areas
Cancer; Digestive system; Lungs and airways; Urinary and reproductive; Pregnancy and women's health; Blood and lymph; Skin and connective tissue; Immune system
Registered trials of its drugs
761

Drugs at this target

StatusCount
Marketed9
Active4
Went quiet6
Stopped9
Status not established1
Total29
DrugStatusFurthest phaseUS protection
RegorafenibMarketedPhase 4Ends 2032
NintedanibMarketedPhase 4Ends 2027
PaliferminMarketedPhase 4Ended 2016
PemigatinibMarketedPhase 3Ends 2040
ErdafitinibMarketedPhase 3Ends 2033
InfigratinibMarketedPhase 3Ends 2029
FutibatinibMarketedPhase 3Ends 2036
FexagratinibActivePhase 3none listed
BemarituzumabStoppedPhase 3none listed
BrivanibStoppedPhase 3none listed
LucitanibStoppedPhase 3none listed
RogaratinibStoppedPhase 3none listed

12 of 29 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A12
Route B8
Engaged5
Undetermined6
Total on the list31
Three companies on route A or B, with the route only
CompanyRoute
IncyteRoute B
AmgenRoute A
Bristol Myers SquibbRoute A

The other 28 companies at FGFR2

In the product

31 companies in all; 28 are not named here, and no score is.

See the 31 companies at FGFR2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at FGFR2

Other targets in cancer

Companies holding approvals at FGFR2